Loading...
Effective medical education that addresses the multi-cultural diversity of our country.
(305) 630-9414
Call Now
Home
Conferences
On-Demand Webinars
Our Culture
Accreditation
Contact Us
Evaluation Form
Home
Evaluation Form
Overcoming Disparities in the Diagnosis and Management of Migraine
ACOI Satellite Symposium - October 30, 2024
Scottsdale, AZ
a
b
c
First Name
*
Last Name
*
Email
*
I am a
*
Physician
Non-Physician
Please rate how well the following learning objectives were met:
Made it Worse
No Change
Made it Better
Implement strategies to successfully diagnose acute migraine across all demographics
Made it Worse
No Change
Made it Better
Overcome treatment inertia when managing patients of a diverse and/or lower socioeconomic status by initiating dialogue to gain patient trust leading to improved outcomes
Made it Worse
No Change
Made it Better
Recognize that migraine leads to a negative impact on patient quality of life and disease burden
Made it Worse
No Change
Made it Better
Explain the role of CGRP in migraine and prevention of medication overuse headache
Made it Worse
No Change
Made it Better
Yes
No
Was the presentation fair balanced and objective?
*
Yes
No
The speaker was knowledgeable, effective, and had expertise regarding migraine treatment
*
Yes
No
The presentation improved my knowledge and competence in managing patients with migraine
*
Yes
No
Were you satisfied with the presentation?
Yes
No
Of the patients you will see this month, about how many (number) will benefit from the information you learned today?
*
Select...
1-3
4-6
7-10
11-14
15 or more
None
Which migraine treatment regimen is least likely to contribute to medication overuse headache when used for at least 3 months?
*
Select...
sumatriptan over 10 days per month
acetaminophen over 15 days per month
rimegepant over 15 days per month
ibuprofen over 15 days per month
According to the American Headache Society 2024 position statement on the use of CGRP inhibitors, which of the following is TRUE?
*
Select...
Evidence that suggests that a delaying effective preventive treatment may result in the disorder becoming more refractory
Access limitations for those patients with migraine and reduced resources are at the least burden
Trial and error approach of first line, oral, non-specific preventive treatments, may significantly reduce costs and burden for migraine as compared to CGRP inhibitors
Longer trials for up to 6 months may improve the chances of responding to non-specific oral therapies
How often do you CURRENTLY use this strategy? I screen for disability in people diagnosed with migraine routinely across all demographics.
*
Select...
Never
Not Often
Sometimes
Often
Always
Now that you have heard this presentation, how often do you PLAN TO USE the above strategy?
*
Select...
Never
Not Often
Sometimes
Often
Always
How often do you CURRENTLY use this strategy? I utilize shared decision making when considering migraine specific therapies for acute and preventive treatment.
*
Select...
Never
Not Often
Sometimes
Often
Always
Now that you have heard this presentation, how often do you PLAN TO USE the above strategy?
*
Select...
Never
Not Often
Sometimes
Often
Always
Which of the following barriers or challenges that you encounter in your care of patients or practice will this presentation help you overcome?
*
Engaging patients and caregivers in shared decision-making
Coordinating care with interprofessional team
Patient adherence
Decision-making in the presence of conflicting evidence
Lack of training/experience with this specific topic
Cost/reimbursement/therapy approval status
I do not encounter barriers in the care of patients/my practice
Not listed. Please indicate in section at the end of this evaluation form.
Please provide your License number and state where you are licensed so we can report to PARS
List any questions and/or comments you still have
Submit Evaluation
